hiPSCs disease models provide a new platform for accelerating drug screening and developing personalized medicine. Over the years, Creative Bioarray has worked to continuously improve the efficiency of cell reprogramming and develop iPSC-based drug screening technologies to help identify new therapeutic approaches for patients. We offer specialized solutions to support your research projects in the field of drug discovery.
Introduction
High-throughput screening is typically performed in the early stages of drug discovery and is used to rapidly assess the properties of thousands of compounds to screen for safe and effective drug candidates. The development of high-throughput drug screening technologies plays an important role in promoting the widespread use of high-tech and scientific research results in pharmaceutical science research. The development of cell reprogramming technologies allowing the creation of hiPSC from patients with specific diseases provides a promising method to determine different drug sensitivities through high-throughput screening.
To date, iPSC-based drug screening is in its infancy, but significant progress is expected in this area. Because hiPSC retains the genetic makeup of patients, iPSC-based drug screening represents a fast-track method to facilitate drug discovery and makes it feasible to identify compounds that may have a disproportionate impact on certain patient populations. As these technologies are further refined, they may play a key role in drug development as well as in identifying new treatments for patients.
Fig.1 Human iPS cell derivation, differentiation and applications. (Bellin, 2012)
Solutions for Drug Screening based on Cell Reprogramming
Researchers at Creative Bioarray are working to improve iPSC technology and develop iPSC-based drug screening methods. In addition, we have developed a combination of pluripotent- and 3D organoid-based approaches. To help our customers with iPSC-based compound screening, we propose the following solutions:
- Assay development, which is critical for establishing cell models and screening endpoints representing disease-related phenotypes.
- Primary screening, which involves testing large or small collections of compounds to identify putative disease modifiers.
- Secondary screening and validation, rigorously verifying the efficacy and potential molecular targets of compounds hit by primary screening.
- In vivo testing, confirming the efficacy and safety of compounds in whole organisms with disease-causing mutations.
Advantages
- Reliable screening workflow
- Powerful and advanced data analysis tools
- High quality and efficient services
- Comprehensive and targeted solutions
Creative Bioarray is an international biotechnology company focused on the field of cell reprogramming. We provide total solutions for our customers' research in iPSC-based drug screening. Our professionalism and innovation can offer strong support for your research projects. If you want more details about our services, please feel free to contact us.
Reference
- Bellin, M.; et al. Induced pluripotent stem cells: the new patient?. Nature reviews Molecular cell biology. 2012, 13(11): 713-726.